A phase II/III trial of bitopertin monotherapy compared with placebo in patients with an acute exacerbation of schizophrenia -- Results from the CandleLyte study / Dragana Bugarski Kirola en European Neuropsychopharmacology, Año 2014 - Vol. 24 - No.7 (Julio)

Público ISBD [artículo]  inEuropean Neuropsychopharmacology > Año 2014 - Vol. 24 - No.7 (Julio) . - pp. 1024-1036 Título : A phase II/III trial of bitopertin monotherapy compared with placebo in patients with an acute exacerbation of schizophrenia -- Results from the CandleLyte study Tipo de documento: texto impreso Autores: Dragana Bugarski Kirola, Autor ; Alice Wang, Autor ; Danielle Abi Saab, Autor Fecha de publicación: 2021 Artículo en la página: pp. 1024-1036 Idioma : Inglés (eng) Idioma original : Inglés (eng) Palabras clave: Esquizofrenia, Inhibidor de la recaptación de glicina, Bitopertina, Monoterapia, Exacerbación aguda, Receptor de NMDA Resumen: Bitopertin is a glycine reuptake inhibitor postulated to improve N-methyl-d-aspartate receptor hypofunction by increasing synaptic glycine concentrations. This randomised, double-blind, placebo- and active-controlled phase II/III trial evaluated the efficacy and safety of bitopertin monotherapy over 4 weeks in patients with acute exacerbation of schizophrenia. Link: ./index.php?lvl=notice_display&id=27018 [artículo] A phase II/III trial of bitopertin monotherapy compared with placebo in patients with an acute exacerbation of schizophrenia -- Results from the CandleLyte study [texto impreso] / Dragana Bugarski Kirola, Autor ; Alice Wang, Autor ; Danielle Abi Saab, Autor . - 2021 . - pp. 1024-1036. Idioma : Inglés (eng) Idioma original : Inglés (eng) in European Neuropsychopharmacology > Año 2014 - Vol. 24 - No.7 (Julio) . - pp. 1024-1036 Palabras clave: Esquizofrenia, Inhibidor de la recaptación de glicina, Bitopertina, Monoterapia, Exacerbación aguda, Receptor de NMDA Resumen: Bitopertin is a glycine reuptake inhibitor postulated to improve N-methyl-d-aspartate receptor hypofunction by increasing synaptic glycine concentrations. This randomised, double-blind, placebo- and active-controlled phase II/III trial evaluated the efficacy and safety of bitopertin monotherapy over 4 weeks in patients with acute exacerbation of schizophrenia. Link: ./index.php?lvl=notice_display&id=27018

---

1 (1 - 1 / 1)